What is PLx Pharma?
PLx Pharma Inc. is a specialty pharmaceutical company distinguished by its clinically-validated and patent-protected PLxGuard drug delivery platform. This innovative technology is engineered to precisely target the release of active pharmaceutical ingredients to specific segments of the gastrointestinal tract. The company posits that this platform can enhance drug absorption for numerous existing and developmental medications, while concurrently mitigating the risk of gastrointestinal adverse effects such as erosions and ulcers, particularly those associated with certain drug classes.
How much funding has PLx Pharma raised?
PLx Pharma has raised a total of $9.3M across 2 funding rounds:
Debt
$1.3M
Share Placement
$8M
Debt (2016): $1.3M, investors not publicly disclosed
Share Placement (2020): $8M led by West Asset Management LLC and MSD Capital , L.P.
Key Investors in PLx Pharma
West Asset Management LLC
West Asset Management LLC is identified as a participant in the company's funding round. Further details on their investment focus are not publicly available.
MSD Capital , L.P.
MSD Capital, L.P. has provided backing to PLx Pharma. As a significant investment firm, their participation suggests confidence in the company's strategic direction and technological advancements.
What's next for PLx Pharma?
The recent major strategic investment signals a pivotal growth phase for PLx Pharma, likely enabling the company to accelerate the development and commercialization of its PLxGuard platform. This infusion of capital is expected to support expanded clinical trials, regulatory submissions, and the scaling of manufacturing capabilities. The company's focus on improving drug efficacy and safety positions it to address significant unmet needs within the pharmaceutical market, potentially leading to strategic partnerships or market penetration.
See full PLx Pharma company page
